FDA officials are off on a three-week sprint to review J&J COVID-19 vaccine data

FDA officials are off on a three-week sprint to review J&J COVID-19 vaccine data


Johnson & Johnson released data from its vaccine clinical trial last week.

Johnson & Johnson announced yesterday that it had officially asked the Food and Drug Administration to authorize its COVID-19 vaccine, kicking off a process that will send its one-shot immunization through a gauntlet of analysts and experts.

If all goes as expected and the agency agrees that the benefits of the vaccine outweigh the risks, the United States could have a third shot available by the end of February. Experts hope that this vaccine — which only takes one dose and can be stored in the refrigerator — could accelerate the United States’ vaccination campaign.

Over the next few weeks, FDA officials will work at breakneck speeds to review the data submitted by Johnson & Johnson. Then, they’ll write up a report and submit it to…

Continue reading…

Source:

This post was originally created on this site & curated for Mamizi members